Divi’s Laboratories Limited Q3 FY24 Earnings Conference Call February 10, 2024
Generic business segment:
We expect the products with recent regulatory filings to fuel our growth beyond the Financial Year 2025
The custom synthesis segment is on the rise, particularly with the 2 major projects from the big pharma entering into full-scale production where we expect their contribution to increase further in the coming quarters.
We have several molecules at various regulatory stages for our customers. With the expanded production capacity for both large and small-volume products, we are ready for new opportunities.
We are actively involved in the peptide building blocks used in the new anti-diabetic and anti-obesity drugs and are strategically focused on developing this specialized portfolio.
On the CAPEX front:
- Our forward momentum continues with unit 3 infrastructural establishments. The production activity in the 200-acre phase I greenfield project will commence in Q2 of 2024-25.
- Exports for the quarter continued to be around 87%. Exports to Europe and America are about 71% for the quarter. The product mix for generics to custom synthesis is 54% and 46% for the quarter.
Subscribe To Our Free Newsletter |